Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

AUG 31, 2014 - Forbes

A Must Read - Share

Signify Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug

The controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the US, but it is under development by Amgen for a heart failure indication.

Tags: Signify Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug,  Amgen Latest News

AUG 31, 2014 - Forbes

A Must Read - Share

Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug

The controversial drug ivabradine just got a little more controversial. The drug, which is marketed by Servier under the brand names of Corlentor and Procoralan, is available in Europe and elsewhere and is used for the treatment of heart failure and stable angina. The drug is not available in the US, but it is under development by Amgen for a heart failure indication.

Tags: Trial Provokes Sound And Fury Over Controversial Servier and Amgen Drug,  Amgen Latest News

AUG 29, 2014 - Zacks Investment Research

A Must Read - Share

Amgen Submits Regulatory Application for PCSK9 Inhibitor - Analyst Blog

Amgen Inc. (AMGN) submitted a Biologics License Application (BLA) seeking FDA approval for its PCSK9 inhibitor, evolocumab (AMG 145) for the treatment of high cholesterol.

Tags: Amgen Submits Regulatory Application for PCSK9 Inhibitor - Analyst Blog,  Amgen Latest News

AUG 27, 2014 - Investopedia

A Must Read - Share

Who are Amgen Inc.'s (AMGN) main competitors?

Biotech giant Amgen (AMGN) list of competitors is lengthy and formidable. Learn the major companies Amgen competes with.

Tags: Who are Amgen Inc.'s (AMGN) main competitors?,  Amgen Latest News

AUG 27, 2014 - TheStreet

A Must Read - Share

Why Amgen (AMGN) Stock Hit a One-Year High Today

NEW YORK (TheStreet) --aAmgena hit a 52-week high of $137.99 on Wednesday after the Food and Drug Administration granted priority review for the biopharmaceutical company's New Drug Application for its prospective chronic heart failure treatment drug ivabradine. Amgen designed ivabradine to slow patients' heart rate without the negative side effects ofamyocardial contractility or ventricular repolarization.aThe FDA gives priority review designations ...

Tags: Why Amgen (AMGN) Stock Hit a One-Year High Today,  Amgen Latest News